Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer's disease

Alzheimer's and Dementia

Volumn 8, Issue 3, 2012, Pages 219-226

  Côté, Sharlène ^a,b   Carmichael, Pierre Hugues ^a   Verreault, René ^a,b   Lindsay, Joan ^a,c   Lefebvre, Jean ^b   Laurin, Danielle ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

All cognitive disorders dementia; Alzheimer's disease; Incidence studies; MCI (mild cognitive impairment); Risk factors in epidemiology

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; COGNITIVE IMPAIRMENT NOT DEMENTIA; COMORBIDITY; DEMENTIA; DISEASE ASSOCIATION; DRUG USE; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; GEOLOGICAL TIME; GROUPS BY AGE; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL RATE; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COGNITION DISORDERS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; NEUROPSYCHOLOGICAL TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84860477341     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2011.03.012     Document Type: Article

References (54)

1. Canadian Study of Health and Aging: study methods and prevalence of dementia CMAJ 150 1994 899 913
2. Alzheimer Society of Canada. Rising tide: the impact of dementia on Canadian society; 2010. ISBN 978-0-9733522-2-1. Available at: http://www.lifeandminds.ca/uploads/articles/feature-article-document- 271262882528.pdf.
3. S.A. Shumaker, C. Legault, S.R. Rapp, L. Thal, R.B. Wallace, and J.K. Ockene Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial JAMA 289 2003 2651 2662 (Pubitemid 37430136)
4. P.P. Zandi, J.C. Anthony, A.S. Khachaturian, S.V. Stone, D. Gustafson, and J.T. Tschanz Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study Arch Neurol 61 2004 82 88 (Pubitemid 38067418)
5. M.G. Isaac, R. Quinn, and N. Tabet Vitamin E for Alzheimer's disease and mild cognitive impairment Cochrane Database Syst Rev 2008
6. R.C. Petersen Mild cognitive impairment: transition between aging and Alzheimer's disease Neurologia 15 2000 93 101 (Pubitemid 30340226)
7. R.C. Petersen, R.O. Roberts, D.S. Knopman, B.F. Boeve, Y.E. Geda, and R.J. Ivnik Mild cognitive impairment: ten years later Arch Neurol 66 2009 1447 1455
8. H. Chertkow, Z. Nasreddine, Y. Joanette, V. Drolet, J. Kirk, and F. Massoud Mild cognitive impairment and cognitive impairment, no dementia: part A, concept and diagnosis Alzheimers Dement 3 2007 266 282 (Pubitemid 47553568)
9. S.T. Farias, D. Mungas, B.R. Reed, D. Harvey, and C. DeCarli Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts Arch Neurol 66 2009 1151 1157
10. F. Massoud, S. Belleville, H. Bergman, J. Kirk, H. Chertkow, and Z. Nasreddine Mild cognitive impairment and cognitive impairment, no dementia: part B, therapy Alzheimers Dement 3 2007 283 291 (Pubitemid 47553566)
11. M.L. Jenkinson, M.R. Bliss, A.T. Brain, and D.L. Scott Rheumatoid arthritis and senile dementia of the Alzheimer's type Br J Rheumatol 28 1989 86 88
12. K. Andersen, L.J. Launer, A. Ott, A.W. Hoes, M.M. Breteler, and A. Hofman Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study Neurology 45 1995 1441 1445
13. B.A. In't Veld, A. Ruitenberg, A. Hofman, L.J. Launer, C.M. van Duijn, and T. Stijnen Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease N Engl J Med 345 2001 1515 1521 (Pubitemid 33144916)
14. W.F. Stewart, C. Kawas, M. Corrada, and E.J. Metter Risk of Alzheimer's disease and duration of NSAID use Neurology 48 1997 626 632 (Pubitemid 27120096)
15. J. Lindsay, D. Laurin, R. Verreault, R. Hebert, B. Helliwell, and G.B. Hill Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging Am J Epidemiol 156 2002 445 453 (Pubitemid 34976983)
16. M. Etminan, S. Gill, and A. Samii Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies BMJ 327 2003 128
17. B.A. In't Veld, L.J. Launer, A.W. Hoes, A. Ott, A. Hofman, and M.M. Breteler NSAIDs and incident Alzheimer's disease. The Rotterdam Study Neurobiol Aging 19 1998 607 611 (Pubitemid 29117129)
18. P.P. Zandi, J.C. Anthony, K.M. Hayden, K. Mehta, L. Mayer, and J.C. Breitner Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study Neurology 59 2002 880 886
19. K.M. Hayden, P.P. Zandi, A.S. Khachaturian, C.A. Szekely, M. Fotuhi, and M.C. Norton Does NSAID use modify cognitive trajectories in the elderly? The Cache County study Neurology 69 2007 275 282 (Pubitemid 47205690)
20. A. Fourrier, L. Letenneur, B. Bégaud, and J.F. Dartigues Nonsteroidal antiinflammatory drug use and cognitive function in the elderly: inconclusive results from a population-based cohort study J Clin Epidemiol 49 1996 1201 (Pubitemid 26348619)
21. S.R. Waldstein, C.R. Wendell, S.L. Seliger, L. Ferrucci, E.J. Metter, and A.B. Zonderman Nonsteroidal anti-inflammatory drugs, aspirin, and cognitive function in the Baltimore longitudinal study of aging J Am Geriatr Soc 58 2010 38 43
22. T. Gómez-Isla, R. Blesa, M. Boada, J. Clarimon, T. Del Ser, and G. Domenech A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study Alzheimer Dis Assoc Disord 22 2008 21 29 (Pubitemid 351651394)
23. L.J. Thal, S.H. Ferris, L. Kirby, G.A. Block, C.R. Lines, and E. Yuen A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment Neuropsychopharmacology 30 2005 1204 1215 (Pubitemid 40720980)
24. The Canadian Study of Health and Aging Working Group The incidence of dementia in Canada Neurology 55 2000 66 73
25. The Canadian Study of Health and Aging: risk factors for Alzheimer's disease in Canada Neurology 44 1994 2073 2080
26. R. Hébert, J. Lindsay, R. Verreault, K. Rockwood, G. Hill, and M.F. Dubois Vascular dementia: incidence and risk factors in the Canadian Study of Health and Aging Stroke 31 2000 1487 1493 (Pubitemid 30437492)
27. J. Lindsay, E. Sykes, I. McDowell, R. Verreault, and D. Laurin More than the epidemiology of Alzheimer's disease: contributions of the Canadian Study of Health and Aging Can J Psychiatry 49 2004 83 91 (Pubitemid 38387417)
28. E.L. Teng, and H.C. Chui The Modified Mini-Mental State (3MS) examination J Clin Psychiatry 48 1987 314 318 (Pubitemid 17138128)
29. Diagnostic and Statistical Manual of Mental Disorders 3rd ed rev 1987 American Psychiatric Association Washington, DC
30. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease Neurology 34 1984 939 944 (Pubitemid 14076461)
31. The ICD-10 classification of mental and behavioral disorders diagnostic criteria for research 1993 World Health Organization Geneva, Switzerland
32. J.E. Graham, K. Rockwood, B.L. Beattie, R. Eastwood, S. Gauthier, and H. Tuokko Prevalence and severity of cognitive impairment with and without dementia in an elderly population Lancet 349 1997 1793 1796 (Pubitemid 27257555)
33. Diagnostic and Statistical Manual of Mental Disorders 4th ed. 1994 American Psychiatric Association Washington, DC
34. G.C. Roman, T.K. Tatemichi, T. Erkinjuntti, J.L. Cummings, J.C. Masdeu, and J.H. Garcia Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop Neurology 43 1993 250 260 (Pubitemid 23060253)
35. A.H. Andersen, and E. Hvidberg New classification of drugs: ATC-code introduced Sygeplejersken 81 1981 24 26
36. D. Laurin, R. Verreault, J. Lindsay, K. MacPherson, and K. Rockwood Physical activity and risk of cognitive impairment and dementia in elderly persons Arch Neurol 58 2001 498 504 (Pubitemid 32217469)
37. D.Y. Lin, L.J. Wei, and Z. Ying Checking the Cox model with cumulative sums of Martingale-based residuals Biometrika 80 1993 557 572
38. H. Tuokko, R. Frerichs, J. Graham, K. Rockwood, B. Kristjansson, and J. Fisk Five-year follow-up of cognitive impairment with no dementia Arch Neurol 60 2003 577 582 (Pubitemid 36427972)
39. L.J. Ritchie, and H. Tuokko Patterns of cognitive decline, conversion rates, and predictive validity for 3 models of MCI Am J Alzheimers Dis Other Demen 25 2010 592 603
40. C.K. Combs, D.E. Johnson, J.C. Karlo, S.B. Cannady, and G.E. Landreth Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists J Neurosci 20 2000 558 567 (Pubitemid 30225558)
41. T. Thomas, T.G. Nadackal, and K. Thomas Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation Neuroreport 12 2001 3263 3267 (Pubitemid 33014359)
42. S.L. Tyas, J. Manfreda, L.A. Strain, and P.R. Montgomery Risk factors for Alzheimer's disease: a population-based, longitudinal study in Manitoba, Canada Int J Epidemiol 30 2001 590 597 (Pubitemid 32600256)
43. S.C. Vlad, D.R. Miller, N.W. Kowall, and D.T. Felson Protective effects of NSAIDs on the development of Alzheimer disease Neurology 70 2008 1672 1677 (Pubitemid 351644133)
44. C.A. Szekely, J.C. Breitner, A.L. Fitzpatrick, T.D. Rea, B.M. Psaty, and L.H. Kuller NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type Neurology 70 2008 17 24
45. P.B. Gorelick Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials Ann N Y Acad Sci 1207 2010 155 162
46. P.S. Aisen, K.A. Schafer, M. Grundman, E. Pfeiffer, M. Sano, and K.L. Davis Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial JAMA 289 2003 2819 2826 (Pubitemid 37430117)
47. S.A. Reines, G.A. Block, J.C. Morris, G. Liu, M.L. Nessly, and C.R. Lines Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study Neurology 62 2004 66 71 (Pubitemid 38082872)
48. P. Pasqualetti, C. Bonomini, G. Dal Forno, L. Paulon, E. Sinforiani, and C. Marra A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease Aging Clin Exp Res 21 2009 102 110
49. A.D.2000 Collaborative Group, P. Bentham, R. Gray, E. Sellwood, R. Hills, and P. Crome Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial Lancet Neurol 7 2008 41 49
50. A.D.A.P.T. Research Group, B.K. Martin, C. Szekely, J. Brandt, S. Piantadosi, and J.C. Breitner Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib Arch Neurol 65 2008 896 905 (Pubitemid 352008472)
51. A.D.A.P.T. Research Group, C.G. Lyketsos, J.C. Breitner, R.C. Green, B.K. Martin, and C. Meinert Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial Neurology 68 2007 1800 1808 (Pubitemid 46791392)
52. J.H. Kang, N. Cook, J. Manson, J.E. Buring, and F. Grodstein Low dose aspirin and cognitive function in the women's health study cognitive cohort BMJ 334 2007 987 10.1136/bmj.39166.597836.BE (Pubitemid 46808364)
53. J.F. Price, M.C. Stewart, I.J. Deary, G.D. Murray, P. Sandercock, and I. Butcher Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial BMJ 337 2008 a1198
54. C. Laino In follow-up analysis of clinical trial, NSAIDs seem to preserve cognitive function in patients with healthy brains Neurology 9 2009 21 22